Join the Oncology Voice Network. Join for Free
Value assessment of oncology drugs using a weighted criterion-based approach
anticancer therapy multicriteria decision analysis value assessment value assessment framework

Value assessment of oncology drugs using a weighted criterion-based approach


Share This Article


Summary

  • The rising cost of anticancer therapy has led to efforts to quantify the overall value of new cancer treatments.
  • Multicriteria decision analysis is used to incorporate multiple criteria and perspectives into value assessment.
  • A diverse, multistakeholder group developed a drug assessment framework (DAF) by identifying and weighting key criteria.
  • The DAF includes 10 criteria: overall survival, progression-free survival, response rate, quality of life, toxicity, unmet need, equity, feasibility, disease severity, and caregiver well-being.
  • The first five criteria (overall survival, progression-free survival, response rate, quality of life, and toxicity) account for approximately 64% of the total weight.
  • DAF scores (0 to 300) reflect the expected impact of the drug and the quality of supporting evidence.
  • Drugs with positive pCODR funding recommendations had higher DAF scores compared to those not recommended (103 vs 63; P = .0007).
  • DAF clinical benefit criteria showed a mild correlation with ESMO-MCBS scores (correlation coefficient, 0.33).
  • Sensitivity analyses showed that varying criteria scores did not change the results.
  • The framework provides a transparent and consistent method to value and prioritize cancer drugs, aiding in the delivery of affordable cancer care.

In recent years, the number of available oncology treatments has significantly increased and these treatments have become more costly, prompting a growing need for sustainable drug funding decision-making processes. In the United States, Canada, and many other countries around the world, cancer drug budgets are increasing at a much faster rate than the gross domestic product per capita. From a societal perspective, there are growing concerns that many of the expensive new cancer medicines that are being developed offer limited meaningful benefit to patients. Cost-constrained health care systems are struggling to provide timely access to new cancer treatments, and high drug acquisition costs inevitably result in significant delays in uptake.

Economically diverse countries face inconsistencies in access that have motivated major oncology societies to develop standardized tools for value assessment. The American Society of Clinical Oncology's (ASCO) framework evaluates new cancer drugs at the individual patient level to inform overall value for clinical decision making. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) assesses clinical benefit and was proposed by ESMO to guide drug approval decisions, although the European Medicines Agency and individual European countries make their own independent funding decisions. In Canada, the pan-Canadian Oncology Drug Review (pCODR) provides national evidence-based funding recommendations using a deliberative framework that considers additional factors beyond the traditional pillars of clinical benefit and cost. Although the dimensions of value considered by pCODR are clearly defined, to the best of our knowledge there is no explicit weighting scheme for these criteria.

Click for Source Download PDF version
anticancer therapy, multicriteria decision analysis, value assessment, value assessment framework

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Explore OVN